Vergelijking
Goserelin vs. Bremelanotide
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Onderzoek (overig)
Onderzoek (overig)
CAS-nr.
65807-02-5
189691-06-3
Molecuulmassa
1269.43 g/mol
1025.18 g/mol
Halfwaardetijd
4.2 h
2.7 h
Sequentie
pGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-Azgly-NH2Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OHWerkingsmechanisme
Goserelin
As a GnRH agonist, goserelin binds to the GnRH receptors of the pituitary gland. Initial stimulation transiently raises luteinizing hormone (LH) and follicle-stimulating hormone (FSH). With continuous receptor occupancy, however, the receptors become desensitized and down-regulated, which reduces LH and FSH secretion and consequently the production of testosterone or estrogen. This mechanistic relationship is documented in the pharmacological literature.
Bremelanotide
Bremelanotide is a cyclic peptide that binds non-selectively to melanocortin receptors (MC1R through MC5R) — with highest affinity at MC4R in the central nervous system. The precise role of MC4R activation in sexual behaviour is not fully understood; animal data show effects on hypothalamic circuits. Peripheral effects (blood pressure, hyperpigmentation) are attributed to MC1R/MC2R.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
4
5
waarvan bij mensen
4
5
Geregistreerde effecten
3
3
Openstaande tegenstrijdigheden
1
1
Gedocumenteerde bijwerkingen
2
2
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Goserelin and Bremelanotide?
- Goserelin is classified as "Onderzoek (overig)", while Bremelanotide is classified as "Onderzoek (overig)". Goserelin: Goserelin is a synthetic decapeptide and an agonist of gonadotropin-releasing hormone (GnRH). The medical literature describes it as a hormonal agent that suppresses the release of sex hormones through sustained receptor stimulation. Regulatory-approved indications include prostate cancer, advanced breast cancer, endometriosis, and endometrial thinning, among others. Bremelanotide: Synthetic cyclic heptapeptide acting as a non-selective melanocortin-receptor agonist. FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in pre-menopausal women. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Goserelin or Bremelanotide?
- The highest available evidence level is "Humane RCT" for Goserelin and "Humane RCT" for Bremelanotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Goserelin and Bremelanotide in Germany and the United States?
- Duitsland: Goserelin — Op recept, Bremelanotide — Niet goedgekeurd. Verenigde Staten: Goserelin — Op recept, Bremelanotide — Op recept. These are factual summaries with source and review date on the individual pages.